KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Accumulated Expenses: 2011-2012

  • Halozyme Therapeutics' Other Accumulated Expenses rose 212.99% to $1.5 million in Q4 2012 from the same period last year, while for Dec 2012 it was $1.5 million, marking a year-over-year increase of 212.99%. This contributed to the annual value of $1.5 million for FY2012, which is 212.99% up from last year.
  • Halozyme Therapeutics' Other Accumulated Expenses amounted to $1.5 million in Q4 2012, which was up 212.99% from $481,365 recorded in Q4 2011.
  • In the past 5 years, Halozyme Therapeutics' Other Accumulated Expenses ranged from a high of $1.5 million in Q4 2012 and a low of $481,365 during Q4 2011.
  • For the 2-year period, Halozyme Therapeutics' Other Accumulated Expenses averaged around $993,990, with its median value being $993,990 (2011).
  • Data for Halozyme Therapeutics' Other Accumulated Expenses shows a peak YoY skyrocketed of 212.99% (in 2012) over the last 5 years.
  • Halozyme Therapeutics' Other Accumulated Expenses (Quarterly) stood at $481,365 in 2011, then surged by 212.99% to $1.5 million in 2012.